OrthoPediatrics Corp. (KIDS) 12-Month Stock Forecast & Price Target Cone

KIDS scores 50 out of 100, earning a letter grade of D and a verdict of "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

• Fundamental Cash Engine: 9 / 20. The rating cites ROIC of -7.3% and FCF yield of -1.94%. Both figures indicate the business is not currently generating returns on capital or free cash flow relative to its market value. This is the weakest pillar in relative terms and the main reason the overall score sits in the D range.
• Whale 13F Flow: 16 / 20. The rating reads this as institutional accumulation and options positioning.
• Insider Conviction: 3 / 20. The rating cites SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar, suggesting insider and congressional activity is not offering a supportive signal.
• Macro Regime Fit: 10 / 20. The rating cites Beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move broadly in line with the market, offering neither defensive protection nor amplified upside on a market-driven basis.
• Forensic Balance Sheet: 12 / 20. The rating cites Altman Z of 3, Piotroski F of 5/9, and Debt/Equity of 0.29. These are mid-range readings: the Debt/Equity ratio is modest, but the Piotroski score is neither strong nor weak.

For a prospective investor evaluating the stock today, the picture is mixed in a way that leans cautious. The fundamental and insider pillars carry the most weight against the stock, while institutional flow provides the main counterpoint. The 52-week range of $14.42 to $32.62 places the current price of $31.52 near the top of that band, which means much of the recent price appreciation is already reflected in the quote, and the cash-flow metrics do not yet justify it on a fundamental basis. The rating is a scoring framework, not a recommendation, and the investor should weigh these pillar readings against their own research.

OrthoPediatrics Corp. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The company's market capitalization is $0.8B.

Revenue rose from $148.7M in FY 2023 to $236.3M in FY 2025, while operating losses persisted across all three periods. The market data reports a gross margin of 73.1%, an operating margin of -16.6%, and a net margin of -16.8%. Per the RQD rating, ROIC is -7.3% and the Forensic Balance Sheet pillar cites an Altman Z-Score of 3 and a Piotroski F-Score of 5/9. The source reports Debt/Equity of 0.29. Cash fell from $43.8M to $19.6M across FY 2024 to FY 2025 while debt rose from $73.0M to $99.8M.

• 🐂 Primary Bull Case: Institutional accumulation (Whale 13F pillar at 16/20) and recent guidance raises support upside momentum. With Fundamental Cash Engine at 9/20 (ROIC -7.3%, FCF yield -1.94%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $14.42 – $32.62 52-week range.
• 🐻 Primary Bear Case: Negative ROIC of -7.3%, negative FCF yield of -1.94%, and weak insider conviction (3/20) signal the stock is priced above its cash-generation fundamentals. Investors must weigh current valuation against -16.6% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The sector is recorded as Health Care and the industry as Medical/Dental Instruments, but the source does not map any specific suppliers, customers, or peers.

• Key Question #1: What are the current consensus rating and price targets, since the analyst data section is empty?
• Key Question #2: What is the reason for the decline in cash from $43.8M to $19.6M alongside rising debt, and what is the company's stated plan for funding operating losses?
• Key Question #3: How sensitive is KIDS's 73.1% gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?